News

Filter

1 to 9 of 40 results

Amarin plunges as FDA denies appeal on ANCHOR trial SPA

Amarin plunges as FDA denies appeal on ANCHOR trial SPA

14-09-2014

Shares of US biotech firm Amarin Corp tanked 23.7% to $1.38 on Friday in heavy trading, when the company…

AmarinCardio-vascularGlaxoSmithKlineLovazaPharmaceuticalRegulationVascepa

Mylan to acquire US rights to Arixtra Injection from Aspen

Mylan to acquire US rights to Arixtra Injection from Aspen

10-09-2014

US generic drugs major Mylan has entered into an agreement to acquire the US commercialization, marketing…

ArixtraAspen PharmacareCardio-vascularGenericsGlaxoSmithKlineMergers & AcquisitionsMylanUSA

GSK launches Phase III trial with losmapimod in acute coronary syndrome

GSK launches Phase III trial with losmapimod in acute coronary syndrome

06-06-2014

UK pharma major GlaxoSmithKline has announced the start of a pivotal Phase III study, LATITUDE-TIMI 60,…

Cardio-vascularCardiologyGlaxoSmithKlinelosmapimodPharmaceuticalResearchUK

Another disappointment for GlaxoSmithKline with darapladib

Another disappointment for GlaxoSmithKline with darapladib

13-05-2014

UK Pharma giant GlaxoSmithKline today announced disappointing headline results from its second Phase…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearch

Teva launches first generic Lovaza in USA

Teva launches first generic Lovaza in USA

08-04-2014

Israel-based Teva Pharmaceutical Industries says it has received US Food and Drug Administration approval…

Cardio-vascularGenericsGlaxoSmithKlineLovazaMarkets & MarketingRegulationTeva Pharmaceutical IndustriesUSA

ACC 2014: GSK’s darapladib disappoints in Ph III trial

ACC 2014: GSK’s darapladib disappoints in Ph III trial

31-03-2014

UK pharma major GlaxoSmithKline (LSE: GSK) presented disappointing data from its pivotal Phase III STABILITY…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearchUKUSA

Amarin calls on FDA to extend Vascepa exclusivity by five years

28-02-2014

US biotech firm Amarin has filed with a federal court requesting it to order the US Food and Drug Administration…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLegalLovazaNorth AmericaUSAVascepa

GlaxoSmithKline’s darapladib flops in Ph III CHD trial

GlaxoSmithKline’s darapladib flops in Ph III CHD trial

12-11-2013

UK pharma giant GlaxoSmithKline saw its shares dip 1.3% to £16.29 in mid-morning trading, after the…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearch

1 to 9 of 40 results

COMPANY SPOTLIGHT

Menarini

Back to top